Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
what happened to these guys? I was an investor several years ago and believed in them wholeheartedly. They don't seem to have it together
APSN SEC Suspension:
http://www.sec.gov/litigation/suspensions/2014/34-72402.pdf
Order:
http://www.sec.gov/litigation/suspensions/2014/34-72402-o.pdf
Admin Proceeding:
http://www.sec.gov/litigation/admin/2014/34-72403.pdf
Hearing that Eli Lilly and APSN are on the verge of making some big announcement. Maybe a big time PR is coming! IMO. Get the word out!!!
WHere is this stock going and what caused its decline?
Any hope???
Expedition 3 trial, paid for by Eli Lilly, hopes to gain approval before being released...read somewhere that the Alzheimer's drug and pharmaceutical industry will demand somewhere in the neighborhood of 5 billion a year...this explains why the big boys (Eli Lilly, Pfizer and Novartis) are shoring up this Solanezamub product for the market, perfecting the outcome effect wished...and gaining FDA approval in the process.
Look above and you'll see that Pfizer and Novartis pharmaceutical are getting involved in the research area...seems Eli Lilly is also involved, at some level, with getting the drug currently in the pipeline, to be approved for sale. Seems some of the trials for their drug didn't show enough benefits to those with a certain stage of Alzheimer's disease. This doesn't mean that they're gonna scrap the whole plan, but means there are other pharm companies getting involved in order to "perfect" the drug, to make it better, so the best product evolves from this process...we wait with baited breath...
It's gonna be a few years before this stock does anything substantial...so goes the business of getting the drug into the hands of those who need it most. There are two things to keep in mind, maybe three. 1) Eli Lilly is making its way into China and its market, 2) there are patents expiring on medicines which had brought in plenty of revenue for Eli Lilly, 3) the population (baby boomers) are getting older, Alzheimer's is not really understood, yet Dr. Davies is doing some remarkable stuff which other researchers for other companies haven't been able to do, good things for this emerging market.
It turns out that J&J, along with Pfizer, haven't been able to uncover a drug for Alzheimer's which has succeeded in trials as well as the one produced in the Applied Neurosolutions/Eli Lilly team. Hence, the Alzheimer's division for each company has closed it's doors and moved on...leaving Dr. Peter Davies in good position to find the most effective Alzheimer's drug for the increasing Alzheimer's market.
Also, Eli Lilly has agreed to pitch in about 25.5 million $'s when specific timelines are met by Applied Neurosolutions.
Google the specifics about the latest agreement between Eli Lilly and Applied Neurosolutions and you'll find the answer's to other questions you may have. Get curious as the info you find will help in recognizing there's good being done here.
Eli Lilly and Applied Neurosolutions have an agreement which, while certain timelines are fulfilled, increases the income and research potential in finding a viable drug for Alzheimer's disease. Dr. Peter Davies is a well renowned, world renowned research analyst for Alzheimer's, he's under contract with Applied Neurosolution's for this very reason. Pfizer and Johnson & Johnson have given up research and development of a viable drug, for now.
Keep abreast of updates, successes and failures of trials for the drug Solanezumub and you'll begin to understand the potential capital gains your investment will provide.
Google Applied Neurosolutions every once in awhile as development of this drug and FDA approval will eventually come...
Be Well...
Trials for Alzheimer’s Drug Halted After Poor Results
By KATIE THOMAS
Published: August 6, 2012
FACEBOOK
TWITTER
GOOGLE+
E-MAIL
SHARE
PRINT
REPRINTS
Johnson & Johnson and Pfizer announced on Monday that they were halting development of a closely watched Alzheimer’s drug after two clinical trials failed to show that it was effective in patients with mild to moderate forms of the disease.
Add to Portfolio
Pfizer Inc
Johnson & Johnson
Go to your Portfolio »
Late last month, results of a large clinical trial of the drug, called bapineuzumab, failed to show that patients — all of whom carried a particular gene that raises the risk of getting Alzheimer’s — improved either cognition or daily functioning compared with a placebo. The companies announced Monday that the results of a second trial, which tested the drug on patients who did not carry the gene, also did not meet its goals.
Because the results of the earlier trial were already known, the decision to discontinue the drug was not altogether unexpected.
Bapineuzumab, like other Alzheimer’s drugs being developed, targets beta amyloid, a protein that has toxic effects on the brain and is believed to be a cause of the disease. Given the failure of the drug, some have called that theory into question.
But Dr. Husseini K. Manji, the global therapeutic area head for neuroscience at Janssen Research and Development, a unit of Johnson & Johnson, said the failed trials did not mean researchers should abandon the beta amyloid theory.
“While we are disappointed in the results of the two bapineuzumab IV studies, particularly in light of the urgent need for new advancements in Alzheimer’s disease, we believe that targeting and clearing beta amyloid remains a promising path to potential clinical benefits for people suffering from this disease,” he said in a news release.
Johnson & Johnson said it expected to record a charge of $300 million to $400 million in the third quarter of this year related to the discontinuation of the trials.
Eli Lilly Might Have an Alzheimer’s Cure
LLY stock set to soar Friday on favorable drug trial
By Jeff Reeves, Editor of InvestorPlace.com | Aug 24, 2012, 9:03 am EST
Popular Posts:
Yay, Certainty in the U.S.! … and Chaos Abroad
5 Risky Games That Investors Play
The Best Fidelity Funds for Your 401(k)
Recent Posts:
Yay, Certainty in the U.S.! … and Chaos Abroad
5 Risky Games That Investors Play
When Is It Time to Sell a Dividend Stock?
View All Posts
How to Pick the Best High-Yield Stocks in Big Pharma
Big news today from Eli Lilly & Co. (NYSE:LLY) — according to reports, the company proved “a statistically significant slowing of cognitive decline in patients with mild Alzheimer’s disease.”
Lilly stock is up 8% in early trading as a result of this potential Alzheimer’s prevention drug known as solanezumab. But forget what this means for Big Pharma; it’s a huge deal if true for the millions of older Americans facing the threat of this disease.
There is a catch: The solanezumab Alzheimer’s drug apparently did not show as much success in patients already in moderate cognitive decline, according to Eli Lilly. In other words, it’s more of a preventative measure for early-stage patients than a cure for those who already suffer dementia.
Another red flag was that adverse affects did crop up including lethargy, malaise and even angina. The solanezumab trial included 2,050 patients in 16 countries, and Eli Lilly’s Alzheimer’s drug was compared with a placebo.
However, the difficulties in treating advanced Alzheimer’s disease and the side effects don’t appear to be deal-breakers for Eli Lilly, and the FDA could very well be pleased with the results considering the pressing need for some kind of cure.
From an investor perspective, Lilly needed this. Its Q2 net profit fell 23% in July because of patent expirations, and a pipeline of new drugs like this solanezumab Alzheimer’s medication are key to future growth.
That’s true for all of Big Pharma, as patent expirations can absolutely devastate a drug’s sales. And for pharmaceutical stock investors, recent developments have been encouraging proof that the old guard aren’t just going to die out as generics take over.
Consider that another pharma stock, Merck & Co. (NYSE:MRK), popped almost 15% in about a month thanks to its osteoporosis treatment, odanacatib. The drug prevents fractures in brittle bones and just finished a successful Phase 3 trial.
The Lilly breakthrough is particularly good for Big Pharma considering a very public setback earlier this month of another Alzheimer’s drug, bapineuzumab — a joint effort from Pfizer (NYSE:PFE), Johnson & Johnson (NYSE:JNJ) and Irish biotech Elan (NYSE:ELN).
Only time will tell how effective this drug will be in the long term and how many patients it will help. But for the time being, there are some signs of hope for those suffering from Alzheimer’s — and their families.
Jeff Reeves is the editor of InvestorPlace.com and the author of “The Frugal Investor’s Guide to Finding Great Stocks.” Write him at editor@investorplace.com or follow him on Twitter via @JeffReevesIP. As of this writing, he did not own any of the stocks named here.
What makes you say Pfizer is helping out?
I do not see news anywhere? Are you just trying to dump
your shares on me? Lol
It looks like Pfizer is also getting in on the business of helping this company along...
Well I sold back when they said they were closing up shop till they found more money.
By the time they announce anything I'm going to need an alzheimer's test.
All it's going to take is a lot of people buying this stock and it's going to fly!!
Nice. I am going to hold on and see what happens. Might as well roll the dice on this one. It was done and now it is alive. It is basically free to me now. I was waiting for it to go to 0. Maybe we will hit a grand slam for once.
News came out today:
Applied NeuroSolutions Announces Increased Scope of Alzheimer's Disease Drug Discovery Collaboration With Eli Lilly and Company
http://www.marketwire.com/press-release/Applied-Neurosolutions-Inc-1094535.html
The stock has increased by 90%, so I don't know if there is more movement. However, another website posted an interesting article:
Applied Neurosolutions (APSN)- the next ATHX?
http://www.tapebeat.com/Companies-Profiles/applied-neurosolutions-apsn-the-next-athx.html
so i guess we might see a movement higher.
Hey Mortimor this might actually work out. I was going to dump some for tax losses but I am going to have to hold on now. It looks like Lilly is stepping up to the plate, The must know something we don't or they must really like what they see. I need this one to go to the moon. I am patient.
UPDATE!! I haven't spoken to management but I'm sure the lights are on and you can see people moving inside.
Applied NeuroSolutions Announces Renewal of Alzheimer’s Disease Drug Discovery Collaboration with Eli Lilly and CompanyBY Business Wire
— 09:33 AM ET 12/08/2009
VERNON HILLS, Ill.--(BUSINESS WIRE)-- Applied NeuroSolutions, Inc. (APSN
) (www.AppliedNeuroSolutions.com), a biotechnology company focused on the development of products for the early diagnosis and treatment of Alzheimer's disease ("AD"), today announced that Eli Lilly and Company (LLY
) has agreed to a one-year renewal of its drug discovery collaboration. Lilly will pay $250,000 to Applied NeuroSolutions (APSN
) for the one-year collaboration renewal.
The original collaboration term was for three years, with two one-year options to extend the collaboration term at Lilly’s sole discretion. Lilly exercised the first one-year option.
“It is very exciting that Eli Lilly and Company (LLY
) believes we are making sufficient progress in our drug discovery efforts to renew the collaboration for another year,” commented Craig S. Taylor, Ph.D., Applied NeuroSolutions’ President and CEO. “The efforts of Peter Davies, Ph.D., our founding scientist, Lilly, and Applied NeuroSolutions (APSN
) have achieved significant internal milestones to date and we are hopeful that continued progress will lead to achievement of our first paid milestone from Lilly in 2010
I know what you mean. It is not even worth trying to sell it anymore.
We're back Mortimer.
At least for a year. Maybe they will actually get something done in the next 12 months. If they actually do get this thing together this stock could be worth a bundle. I am down so much at this point I will just ride it out. Maybe I will get lucky. All my other stocks are pretty much dead.
NEWS!! I told you someone was working there!
Applied NeuroSolutions Updates Promising Results for a Blood-Based Test for Alzheimer's DiseaseBY Business Wire
— 5:33 PM ET 10/08/2009
VERNON HILLS, Ill.--(BUSINESS WIRE)-- Applied NeuroSolutions, Inc. (APSN
) (www.AppliedNeuroSolutions.com), a biotechnology company focused on the development of products for the early diagnosis and treatment of Alzheimer's disease ("AD"), today confirmed, as previously disclosed in July 2009, that it has achieved sufficient analytical sensitivity to detect tau in serum patient samples. This is a key step in the development of a blood-based test to detect AD at an early stage. Based on a further analysis of the preliminary data, the Company believes additional development of the assay, including optimization and validation in key patient population groups, is necessary to determine the specific sensitivity and specificity performance of the assay. The Company is currently raising funds to support continued development and commercialization of this blood-based Alzheimer’s test.
Applied NeuroSolutions, Inc. (APSN
) also announces the Company website has been updated, including a current Corporate Presentation.
About Applied NeuroSolutions (APSN
Loading...
):
Applied NeuroSolutions, Inc. (APSN
Loading...
) is developing diagnostics and therapeutics to detect and treat Alzheimer's disease (AD) building on discoveries originating from the Albert Einstein College of Medicine. Applied NeuroSolutions (APSN
Loading...
) is in a collaboration with Eli Lilly and Company to develop novel therapeutic compounds to treat the progression of AD. For its diagnostic pipeline, Applied NeuroSolutions (APSN
Loading...
) is focused on both cerebrospinal fluid (CSF) and serum tests to detect AD at a very early stage. The CSF based P-Tau 231 test now being offered for use in clinical trials can effectively differentiate AD patients from those with other neurological diseases that have similar symptoms. There is currently no FDA approved diagnostic test to detect AD. Alzheimer's disease currently afflicts over five million Americans, and the world market for AD therapy is currently estimated to be nearly 30 million patients. For more information, visit www.AppliedNeuroSolutions.com
Excitement is growing! This thing is starting to sizzle like fatback in a frying pan!
I told you so!!
Yeah I saw that. But they are reducing the AS also. In the last year their tone has changed. I think they are getting shareholder pressure to start showing profits. Their last few PRs mentioned this summer for their next milestone. It is just a therory but if you reduce your float just before a big PR then you can get your sp up into the dollars instead of pennies and then attract inst. investors. These are not pump and dump CEOs rather they are scientist who just want to invent things and could care less about making money. JMO
Oh I just threw out the "take off" line to see if anyone was watching
On June 5, 2009, the Registrant filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation with the Delaware Secretary of State which serves to effect, as of June 29, 2009, a 1-for-30 reverse split of the Registrant's common stock. As a result of the reverse stock split, every 30 shares of the Registrant's common stock will be combined into one share of common stock, and any fractional shares created by the reverse stock split will be rounded up to whole shares. The reverse stock split affects all of the Registrant's common stock, stock options and warrants outstanding immediately prior to the effective date of the reverse stock split. The reverse split, which was approved by the Registrant's stockholders at the annual meeting held on September 16, 2008, will reduce the number of shares of the Registrant's common stock outstanding from 130,217,808 shares to approximately 4,342,000 shares, and the number of authorized shares of common stock will be reduced from 200,000,000 shares to 100,000,000 shares. The Certificate of Amendment is filed as Exhibit 2.1 hereto.
I dont think sooo!
News out today as well. This is so undervalued. They have 2.5 mill in cash with major partners. This one will boom soon.
http://biz.yahoo.com/bw/080728/20080728005079.html?.v=1
BottomBuster Alert DD Post on APNS.OB (.06) Extremely Undervalued Biotech Play w/Major Partners (Eli Lilly, Takeda, & others) & Strong Financial Backing! Major Alzheimer's Conference this week to set opportunities in motion.
http://www.alz.org/icad/
Dinner Presentation by Lilly to discuss the clinical biomarker of APNS.OB
http://www.appliedneurosolutions.com/doc/APNS_8K_April_2008-Lilly-Milestone.doc
Pfizer to Showcase Alzheimer's Research and Pipeline at Upcoming Alzheimer's Disease Medical Meeting
1:00p ET July 14, 2008 (Business Wire)
Pfizer, Inc announced today that it will present nine abstracts from its Alzheimer's disease (AD) research and development program, including three on the two promising investigational therapies in the early stages of development, at the 2008 Alzheimer's Association International Conference on Alzheimer's Disease (ICAD) in Chicago, July 26-31.
Pfizer will also host an analyst briefing at ICAD to review its neuroscience pipeline and platform on Monday, July 28. In addition, Pfizer will sponsor a satellite symposium, "Innovative Approaches to Alzheimer's Disease: Developing the Next Generation of Treatment," on Tuesday, July 29.
"With the expected huge increase in the incidence of Alzheimer's disease worldwide in the next 25 years, Pfizer's neuroscience team has made this devastating illness our highest priority," said Dr. Liam Ratcliffe, senior vice president and development head for Pfizer Neuroscience. "With new insights into the underlying causes of Alzheimer's discovered in only the past few years, our scientists are working to develop new medicines that improve memory and other cognitive function, and importantly halt or significantly slow the progression of the disease. We are also working on approaches that could lead to earlier and better diagnosis."
Pfizer's investigational compounds target multiple pathways to combat AD, beta amyloid, the harmful protein that builds up in the brains of AD patients; amyloid plaques, the sticky deposits made of beta amyloid fragments that impair the function of brain cells; chronic inflammation of neurons, and loss of function across the synapses (or gaps) between neurons.
Data from Pfizer to be presented at the meeting include:
-- Receptor for Advanced Glycation End-products (RAGE) Antagonist: Pfizer is in collaboration with TransTech Pharma to develop and commercialize a portfolio of RAGE modulators. RAGE is a cell-surface receptor that may play a key role in multiple aspects of AD. Targeting RAGE for Alzheimer's is a novel approach and Pfizer is pioneering this approach in the clinic. -- Initial Phase II data on the safety and tolerability of Pfizer's oral RAGE antagonist known as PF-04494700 will be presented by Dr. Marwan Sabbagh, FAAN, director of The Cleo Roberts Center of Clinical Research at the Sun Health Research Institute in Sun City, AZ, on Wednesday, July 30th at 12:30 p.m. CST. -- Preclinical data on the effect of PF-04494700 on chronic inflammation and buildup of amyloid plaques - two abnormal processes that are implicated in causing damage and death to brain cells in AD - will also be presented by Dr. Jeffrey Webster of TransTech Pharma on Monday, July 28th at 12:30 p.m. CST. -- Humanized Anti-Amyloid Monoclonal Antibody: Preclinical data on the effect of PF-04360365, Pfizer's investigational monoclonal antibody in Phase 1 trials, on beta amyloid levels in the brains of mice will be presented by Dr. Thomas Lanz, Senior Scientist at Pfizer, on Monday, July 28th at 12:30 p.m. CST. Monoclonal antibodies are designed to selectively target a specific protein, which, in the case of AD, is beta amyloid.
Additional Preclinical Research:Pfizer will also present data on a potential blood biomarker that could help in identifying patients with AD; two studies on the role of the brain's immune system in the formation of amyloid plaques; a potential method of using novel imaging and microscopic analysis to quantify AD neuropathology, and early research on an additional investigational Pfizer compound on the inhibition of an enzyme in the brain.
About Alzheimer's Disease
Alzheimer's disease is a progressive disorder characterized by the gradual loss of memory and a decline in cognitive ability; changes in behavior, and a loss in ability to carry out daily activities. It places a tremendous burden on patients, those caring for them, and healthcare systems, costing the U.S. Government more than $148 billion annually. Alzheimer's disease remains one of the world's most undiagnosed diseases, with only one-third of the world's approximately 18 million sufferers receiving treatment.
DISCLOSURE NOTICE: The information contained in this release is as of July 14, 2008. Pfizer assumes no obligation to update any forward-looking statements contained in this release as the result of new information or future events or developments.
This release contains forward-looking information about certain investigational compounds, including their potential benefits in treating Alzheimer's disease, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; decisions by regulatory authorities regarding whether and when to approve any drug applications that may be filed for any such compounds as well as their decisions regarding labeling and other matters that could affect their availability or commercial potential; and competitive developments.
A further description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2007 and in its reports on Form 10-Q and Form 8-K.
Applied NeuroSolutions to Offer P-Tau 231 Test for Use in Alzheimer's Disease Clinical Trials
Tuesday May 13, 9:30 am ET http://biz.yahoo.com/bw/080513/20080513005944.html?.v=1&printer=1
VERNON HILLS, Ill.--(BUSINESS WIRE)--Applied NeuroSolutions, Inc. (OTC BB:APNS - News)(www.AppliedNeuroSolutions.com), a company focused on the development of products for the early diagnosis and treatment of Alzheimer’s disease (“AD”), today announced an initiative to provide its P-Tau 231 cerebrospinal fluid (CSF) test to companies undertaking AD clinical trials. Potential customers, which include pharmaceutical, biotechnology and imaging companies, may use the P-Tau 231 test to aid in screening patients for clinical trials and to track P-Tau 231 levels pre- and post-drug treatment. Applied NeuroSolutions has identified over 50 companies with 100 plus compounds in active clinical development for AD. Revenue generated from providing this service would help support the further development of Applied NeuroSolutions’s diagnostic pipeline, with a goal of delivering a serum-based test for the early diagnosis of AD.
The Company’s P-Tau 231 test has been extensively researched and has overall sensitivity and specificity of 85% to 95%. This is based on a broad range of testing by US and international academic researchers to differentiate patients diagnosed with AD from patients diagnosed with other forms of dementia and other relevant neurological diseases, including major depression, as well as age-matched healthy controls. The data generated from over 2,000 CSF samples have been published in 21 peer-reviewed articles in leading neurology and other scientific journals.
In addition, Applied NeuroSolutions, has to date used the P-Tau 231 test to analyze over 1,500 samples for leading global pharmaceutical companies and is now offering this service to additional customers in response to the growing number of clinical trials to develop better solutions for the increasing AD population. Given the substantial investment required to conduct clinical trials, collection of information provided by the P-Tau 231 test can offer a cost- effective tool to optimize companies’ AD drug development programs.
According to Dr. Mony de Leon, Professor of Psychiatry and Director Center for Brain Health at NYU School of Medicine “P-Tau 231 is now a validated biomarker of neurofibrillary-tangles, a hallmark pathology of Alzheimer’s disease. Among all of the potential AD biomarkers, P-Tau 231 has consistently been the most successful in the diagnosis of AD, not only in the differential diagnosis of Alzheimer’s disease in contrast to other dementias, but also in the very important early stages before the clinical manifestation of AD where the opportunity for therapeutic impact is greatest.”
BS on there chart here today. Someone or MM is manipulating this one. Artificial drop to 4 just when chart was starting to shape up. I wonder how big of a short position there is on this.
held above the 50 day. Next volume surge this moves
This is looking very nice.
Big close here!!! .08! nice volume too.
blocked? wtf? i dont know why. must be a mistake. i fix it now. happens sometimes.
i would reply to your PM but you have me blocked LOL have a nice day :)
sleeper stock.
Yep. I think that by quarter 4 this will be way up. It is going to be a slow steady climb up.
Followers
|
9
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
363
|
Created
|
04/22/05
|
Type
|
Free
|
Moderators |
http://www.appliedneurosolutions.com/index.html
Applied NeuroSolutions, Inc. (APNS) is a development stage biopharmaceutical company focused on diagnostics and therapeutics for the treatment of Alzheimer’s Disease (AD).
Applied NeuroSolutions’ has a long-term agreement with Albert Einstein College of Medicine (AECOM) that grants APNS the exclusive licensing rights to commercialize Dr. Peter Davies’ neurodegenerative disease related discoveries. The technologies are based on the presence of an abnormal form of a protein present in the brains and cerebrospinal fluid (CSF) of AD patients. A specific chemical change in this protein, known as tau, results in an abnormal protein called ptau-231 (tau protein phosphorylated on amino acid 231). The presence of the ptau-231 protein leads to the development of abnormal structures (paired helical filaments and neurofibrillary tangles – the hallmark of Alzheimer’s disease) that contribute to nerve cell death. The correlation between excess amounts of the ptau-231 protein and AD supports the development of diagnostic tests, in vitro drug discovery systems and therapeutics aimed at preventing the formation of this protein and the accompanying neuron-destroying structures. The Company’s technology originated from Dr. Peter Davies, the Judith and Burton P. Resnick Professor of Alzheimer’s Disease Research at the Albert Einstein College of Medicine, and APNS’ scientific founder.
AD Diagnostic Test
Increased amounts of the altered tau protein (ptau-231) in cerebrospinal fluid (CSF) distinguish AD patients from those with other forms of cognitive impairment, providing an early diagnostic test and a method for following disease progression. Applied NeuroSolutions has developed an antibody-based test measuring the protein in the CSF of AD patients and is working on a second-stage blood serum-based test that is expected to be easier to perform and less expensive.
Currently there are no approved diagnostic tests to detect AD and follow its progression. Confirmation of diagnosis is performed through a series of behavioral measurements and brain scans. Definitive diagnosis can be made only from examination of postmortem brain tissue samples. Applied NeuroSolutions’ test would provide a significant breakthrough in supporting definitive early diagnosis.
Alzheimer’s Drug Discovery Platforms
The Company is working on a therapeutic program developed by Dr. Peter Davies based on the common pathway leading to the development of abnormal, destructive brain structures characteristic of AD. This screen can be used to identify drugs that interfere with that pathway, thereby preventing disease development.
Mouse Model for AD
Dr. Davies and the Nathan Kline Institute (NKI) have developed a transgenic mouse model of AD that exhibits Alzheimer-like pathology including accumulation of the abnormal form of tau (p-tau 231) and extensive neuronal death. These mice can be used to test for candidate drugs. The Company and NKI intend to market these models and several drug development companies have expressed interest in them.
Agreements with Pfizer, Novartis
Several major pharmaceutical and biotechnology companies have utilized Applied NeuroSolutions tools and technology to enhance their efforts to develop more effective drugs for Alzheimer's. In January 2003, the Company announced a Research Agreement with Pfizer, Inc. In November 2003, the Company also announced a Research Agreement with Novartis Pharmaceuticals Corporation.
Basis of Research
All of the Company's products and research tools are based upon a distinctive view of the cause and progression of Alzheimer’s disease developed over the past 25 years by Dr. Peter Davies and his colleagues at the Albert Einstein College of Medicine, where Dr. Davies currently serves as the Burton P. and Judith Resnick Professor of Alzheimer's Disease Research.
History
Applied NeuroSolutions was created from a reverse merger of Molecular Geriatrics Corporation into the public company Hemoxymed, Inc. on September 10, 2002. The management team comes from Molecular Geriatrics and has worked together as a group since 1993. The Company changed its name to Applied NeuroSolutions in October 2003 to reflect its focus upon the diagnosis and treatment of AD. The Company’s stock currently trades on the Over-the-Counter Bulletin Board (OTCBB) under the symbol APNS.OB.
The company's address is 50 Lakeview Parkway, Suite 111, Vernon Hills, Illinois, 60061. The telephone number is 847-573-8000 and the fax number is
847-573-8030.
Corporate Presentation http://www.appliedneurosolutions.com/pdf/APNS_Presentation_11_29_07.pdf
The Company’s management team and board of directors include experienced scientists from both academic and pharmaceutical settings as well as senior executives with considerable experience in the development, management and commercialization of biotech and pharmaceutical products. Dr Peter Davies, the Company’s founding scientist is world renowned as an Alzheimer’s disease researcher. The Directors, executive officers, and certain key scientists and advisors of the Company are as follows: |
Ellen R. Hoffing | Chairman of the Board of Directors, President and Chief Executive Officer |
Robert S. Vaters | Director |
Jay B. Langner | Director |
Alan L. Heller | Director |
David C. Tiemeier, Ph.D. | Director |
Peter Davies, Ph.D. | Founding Scientist |
David Ellison, CPA | Chief Financial Officer & Corporate Secretary |
John F. DeBernardis, Ph.D. | Chief Scientific Officer |
For Further Information, Contact:
Ellen Hoffing, President and CEO | Applied NeuroSolutions, Inc. |
Email: | hoffing@appns.com |
Telephone: | (847) 573-8000 |
Fax: | (847) 573-8030 |
Mailing Address: | 50 Lakeview Pkwy, Suite 111 Vernon Hills, IL 60061 |
David Ellison, CFO | Applied NeuroSolutions, Inc. |
Email: | ellison@appns.com |
Telephone: | (847) 573-8000 |
Fax: | (847) 573-8030 |
Mailing Address: | 50 Lakeview Pkwy, Suite 111 Vernon Hills, IL 60061 |
Background
Alzheimer’s disease (AD) is an intractable, chronic and progressively incapacitating disease characterized by the degeneration and death of several types of neurons in certain regions of the brain. Patients affected by the disease initially suffer loss of memory, then a decline of intellectual abilities severe enough to interfere with work and activities of daily living, followed by severe dementia and, finally, death. This illness, currently affecting an estimated 4.5 million people in the United States, and approximately ten million people worldwide, is a leading cause of death behind cardiovascular disease and cancer. While the disease is most common in the elderly, affecting nearly 10% of people age 65 and older and up to 50% of people age 85 and older, it has been diagnosed in patients in their 40’s and 50’s.*
Alzheimer’s disease was first described in 1907 by Dr. Alois Alzheimer, a German psychiatrist who discovered large numbers of unusual microscopic deposits in the brain of a demented patient upon autopsy. These deposits, called amyloid plaques and neurofibrillary tangles, are highly insoluble protein aggregates that form in the brains of AD patients in particular regions, including those involved with memory and cognition. Generally, amyloid plaque is deposited on the surface of neurons, whereas neurofibrillary tangles are formed within neurons. The plaques and tangles are associated with degeneration and loss of neurons. The actual loss of neurons, as well as the impaired function of surviving neurons, is generally believed to be the key neuropathological contributors to the memory loss and dementia that characterizes Alzheimer’s disease.
Applied NeuroSolutions’s core technology in the AD field is based on the work of its founding scientist Dr. Peter Davies and his colleagues at the Albert Einstein College of Medicine. Much of Dr. Davies’ AD research has been involved within an abnormal form of a protein called tau that normally serves to stabilize microtubules, the transit system in nerve cells that directs molecules to their destinations. Excessive phosphorylation of tau prevents it from stabilizing microtubules. This internal neuronal damage leads to the development of the paired helical filaments and neurofibrillary tangles, which are contributing factors to the eventual death of the neurons related to Alzheimer’s disease, and is one of the hallmark pathologies associated with AD. There is a high correlation among the presence of neurofibrillary tangles and cognitive decline in AD.
* Alzheimer’s Association, February 2006
Diagnostic Program
Alzheimer’s disease, at present, can be conclusively diagnosed only by histological examination of the brain by biopsy or autopsy. The diagnosis of patients suspected of having AD is therefore typically made through a process of elimination, by conducting neurological and psychiatric examinations, extensive laboratory tests and a brain scan to rule out other conditions (such as stroke, brain tumor, or depression) with similar symptoms. The definitive AD predictive accuracy of such exams is generally in the range of 75-80%. Costs to patients for such testing currently runs anywhere from $1,000 - $4,000. A simple, predictive, accurate and cost effective diagnostic assay would therefore meet a tremendous medical need.
Applied NeuroSolutions has completed the development of a diagnostic assay utilizing cerebrospinal fluid (CSF). To date, the Company has completed numerous studies comprising in excess of 2,500 CSF samples utilizing this assay. These studies were designed to test the assay’s ability to differentiate patients diagnosed with AD from patients diagnosed with other forms of dementia and relevant neurological diseases, including major depression, as well as healthy controls. These studies have shown the ability of the assay to correctly identify the patients diagnosed with AD with an overall sensitivity and specificity in the 85% to 95% range. The studies have been published in peer reviewed scientific journals such as Neuroscience Letters, Archives of Neurology, Annals of Neurology, Archives of General Psychiatry, Journal of Internal Medicine, Neurobiology of Aging, Neurology, and American Journal of Psychiatry.
These data suggest that the phosphotau may represent an excellent biochemical marker for AD. It detects a characteristic feature of pathophysiology, may allow one to track disease progression and accurately discriminates between AD patients and neurological controls. Several pharmaceutical companies have utilized the Company’s CSF phosphotau assay as a biomarker in the clinical development of therapeutics to treat AD.
Therapeutic Program
The Company’s long-range goal is to discover and develop novel therapeutics to treat AD. Work is being conducted utilizing an in-vitro screen Dr. Davies has developed that could lead to the discovery of a therapeutic to stop the progression of Alzheimer’s disease. The basis for this screen is the discovery of a common pathway that leads to the development of both the neurofibrillary tangles and amyloid plaques.
The market potential for a drug to effectively treat Alzheimer’s disease is extremely large. Currently there are only five drugs approved in the U.S. to treat AD. Four of these drugs are cholinesterase inhibitors and one is an NMDA receptor antagonist. These drugs have limited beneficial effects in treating symptoms associated with AD and are not able to arrest the progression of the disease.
Transgenic Mice Model
To date, no accepted animal model for AD has been developed. However, recently Dr. Peter Davies, through collaboration with a researcher at Nathan Klein Institute (“NKI”), has produced a transgenic mouse that develops neurofibrillary tangles, one of the two hallmark pathologies of Alzheimer’s disease. The pathology in these mice is Alzheimer-like, with hyperphosphorylated tau accumulating in cell bodies and dendrites leading to the production of neurofibrillary tangles. In addition, these transgenic mice have exhibited extensive neuronal death, which accompanies the tau pathology. These new transgenic mice could be used for testing the efficacy of therapeutic compounds. Several pharmaceutical and biotechnology companies have expressed interest in acquiring access to these transgenic mice for testing their therapeutics. The Company and NKI are currently marketing these mice to researchers.
| |||
| |||
Share Structure
Shares Outstanding: | 130.19M |
Float: | N/A |
% Held by Insiders: | 30.19% |
% Held by Institutions: | 1.40% |
Balance Sheet
Total Cash (mrq): 2.56M
Total Cash Per Share (mrq): 0.02 Total Debt (mrq): 0 Total Debt/Equity (mrq): N/A Current Ratio (mrq): 3.042
SEC Filings
http://finance.yahoo.com/q/sec?s=APNS.OB
Recent Headlines
http://finance.yahoo.com/q/h?s=APNS.OB
(2 Year Chart)
Daily Chart
[chart]stockcharts.com/c-sc/sc?s=APNS&p=D&b=5&g=0&i=p70666451736&a=145000874&r=9732[/chart]
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |